Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 117


Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial.

DiNicolantonio JJ, D'Ascenzo F, Tomek A, Chatterjee S, Niazi AK, Biondi-Zoccai G.

Int J Cardiol. 2013 Oct 3;168(3):1739-44. doi: 10.1016/j.ijcard.2013.06.135. Epub 2013 Jul 29.


Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.

Kang HJ, Clare RM, Gao R, Held C, Himmelmann A, James SK, Lim ST, Santoso A, Yu CM, Wallentin L, Becker RC; PLATO Investigators.

Am Heart J. 2015 Jun;169(6):899-905.e1. doi: 10.1016/j.ahj.2015.03.015. Epub 2015 Mar 31.


Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.

Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L.

J Am Coll Cardiol. 2011 Feb 8;57(6):672-84. doi: 10.1016/j.jacc.2010.10.029. Epub 2010 Dec 30.


Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.

Clemmensen P, Dridi NP, Holmvang L.

Cardiovasc Drugs Ther. 2013 Jun;27(3):239-45. doi: 10.1007/s10557-013-6444-2. Review.


Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.

Varenhorst C, Alström U, Scirica BM, Hogue CW, Åsenblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held C.

J Am Coll Cardiol. 2012 Oct 23;60(17):1623-30. doi: 10.1016/j.jacc.2012.07.021. Epub 2012 Sep 26.


Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.

Husted S.

Postgrad Med. 2011 Nov;123(6):79-90. doi: 10.3810/pgm.2011.11.2498. Review.


Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.

Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L.

Eur Heart J. 2011 Dec;32(23):2933-44. doi: 10.1093/eurheartj/ehr422. Epub 2011 Nov 16. Erratum in: Eur Heart J. 2012 Nov;33(21):2750.


Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.

James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L.

Circulation. 2010 Sep 14;122(11):1056-67. doi: 10.1161/CIRCULATIONAHA.109.933796. Epub 2010 Aug 30.


Ticagrelor: a review of its use in the management of acute coronary syndromes.

Deeks ED.

Drugs. 2011 May 7;71(7):909-33. doi: 10.2165/11206850-000000000-00000. Review.


Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.

Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP.

Circulation. 2013 Feb 12;127(6):673-80. doi: 10.1161/CIRCULATIONAHA.112.124248. Epub 2012 Dec 31.


Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.

Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L; PLATO study group.

Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):680-8.


Ticagrelor: a novel reversible oral antiplatelet agent.

Nawarskas JJ, Clark SM.

Cardiol Rev. 2011 Mar-Apr;19(2):95-100. doi: 10.1097/CRD.0b013e3182099d86. Review.


Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D, Komócsi A, Vorobcsuk A, Serebruany VL.

Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Review.


Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial.

Brilakis ES, Held C, Meier B, Cools F, Claeys MJ, Cornel JH, Aylward P, Lewis BS, Weaver D, Brandrup-Wognsen G, Stevens SR, Himmelmann A, Wallentin L, James SK.

Am Heart J. 2013 Sep;166(3):474-80. doi: 10.1016/j.ahj.2013.06.019. Epub 2013 Jul 26.


Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.

Serebruany VL, Dinicolantonio JJ, Can MM, Pershukov IV, Kuliczkowski W.

Cardiology. 2013;126(1):35-40. doi: 10.1159/000350961. Epub 2013 Jul 12.


Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel?

DiNicolantonio JJ, Serebruany VL.

Int J Cardiol. 2013 May 25;165(3):396-7. doi: 10.1016/j.ijcard.2012.11.110. Epub 2012 Dec 27.


Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel.

DiNicolantonio JJ, Tomek A.

Int J Cardiol. 2013 Oct 30;169(2):145-6. doi: 10.1016/j.ijcard.2013.08.085. Epub 2013 Sep 7.


Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.

Liew D, De Abreu Lourenço R, Adena M, Chim L, Aylward P.

Clin Ther. 2013 Aug;35(8):1110-1117.e9. doi: 10.1016/j.clinthera.2013.06.015. Epub 2013 Jul 26.


Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.

Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G, Wallentin L, James SK; PLATO Study Group.

Circulation. 2013 Sep 3;128(10):1055-65. doi: 10.1161/CIRCULATIONAHA.113.002589. Epub 2013 Jul 30.


Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey.

Kaul U, Mansoor AH.

Indian Heart J. 2012 Jan-Feb;64(1):54-9. doi: 10.1016/S0019-4832(12)60012-1. Epub 2012 Mar 26. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk